Free Trial
NASDAQ:EPRX

Eupraxia Pharmaceuticals 11/14/2023 Earnings Report

Eupraxia Pharmaceuticals logo
$5.36 -0.06 (-1.09%)
As of 08/7/2025 03:16 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Eupraxia Pharmaceuticals EPS Results

Actual EPS
-$0.26
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Eupraxia Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eupraxia Pharmaceuticals Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Eupraxia Pharmaceuticals Earnings Headlines

Analysts Set Expectations for EPRX FY2025 Earnings
Trump set to Boost Social Security Checks by 400%?
If you're collecting or planning to collect social security... You should see this presentation about President Trump's Executive Order #14196. Legendary investor Louis Navellier believes it could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%. No wonder the financial times called this new initiative...
See More Eupraxia Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eupraxia Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eupraxia Pharmaceuticals and other key companies, straight to your email.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals (NASDAQ:EPRX) is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

View Eupraxia Pharmaceuticals Profile

More Earnings Resources from MarketBeat